首页> 美国卫生研究院文献>Oncology Letters >The incidence and prognostic value of HER2 overexpression and cyclin D1 expression in patients with gastric or gastroesophageal junction adenocarcinoma in Israel
【2h】

The incidence and prognostic value of HER2 overexpression and cyclin D1 expression in patients with gastric or gastroesophageal junction adenocarcinoma in Israel

机译:以色列胃或胃食管连接腺癌患者HER2过表达和细胞周期蛋白D1表达的发生率及预后价值

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Human epidermal growth factor 2 (HER2) positivity rates for gastric or gastroesophageal junction (GEJ) adenocarcinoma have been reported at 15–25%. Cyclin D1 (BCL1) is a non-specific proliferative marker. The prognostic significance of HER2 and cyclin D1 is inconclusive, with contradictory data. The aim of this study was to evaluate the incidence of HER2 overexpression in gastric or GEJ patients. The presence of a possible correlation between HER2 status and cyclin D1 staining was assessed; both were evaluated as prognostic markers for survival. The clinical data and histological specimens of 150 consecutive patients diagnosed with gastric or GEJ adenocarcinoma, and treated at our hospital from June 2005 to March 2009, were analyzed. Pathological specimens were immunohistochemically stained for HER2. Immunoreactivity was determined according to the scoring system for gastric carcinoma. Cyclin D1 immunoreactivity was also tested. The results demonstrated that HER2 was positive in 14/150 (9.3%) patients. HER2-positive (HER2+) and HER2-negative (HER2) patients did not differ significantly with regard to other clinicopathological parameters. In a multivariate analysis, HER2 positivity was revealed to be a poor prognosis variable (P=0.046; 95% CI, 1.03–3.58). In patients with non-metastatic disease, median survival was 59 months for HER2 and 42 months for HER2+ patients, but this difference was not significant. In patients with metastatic disease, median survival was 9.5 months and 2.5 months for HER2 and HER2+ patients, respectively (P=0.041). Cyclin D1 was not idemonstrated to be a prognostic factor and was not associated with HER2 overexpression. The rate of positive HER2 status in the current group of unselected patients with gastric and GEJ adenocarcinoma was relatively low compared with that observed in the literature. Nevertheless, HER2 positivity was associated with a poor prognosis.
机译:据报道,人类表皮生长因子2(HER2)对胃或胃食管交界处(GEJ)腺癌的阳性率为15–25%。细胞周期蛋白D1(BCL1)是一种非特异性增殖标志物。 HER2和细胞周期蛋白D1的预后意义尚无定论,数据相互矛盾。这项研究的目的是评估胃或GEJ患者中HER2过表达的发生率。评估HER2状态与细胞周期蛋白D1染色之间可能存在的相关性;两者均被评估为生存的预后指标。对2005年6月至2009年3月在我院就诊的150例胃癌或GEJ腺癌连续患者的临床资料和组织学标本进行分析。免疫标本对病理标本进行HER2染色。根据胃癌的评分系统确定免疫反应性。还测试了细胞周期蛋白D1的免疫反应性。结果表明,HER2在14/150(9.3%)患者中呈阳性。 HER2阳性(HER2 + )和HER2阴性(HER2 -)患者在其他临床病理参数方面无显着差异。在多变量分析中,HER2阳性被认为是不良的预后变量(P = 0.046; 95%CI,1.03-3.58)。在非转移性疾病患者中,HER2 -的中位生存期为59个月,HER2 +患者的中位生存期为42个月,但这一差异并不显着。在转移性疾病患者中,HER2 -和HER2 +患者的中位生存期分别为9.5个月和2.5个月(P = 0.041)。 Cyclin D1未被认为是预后因素,并且与HER2过表达无关。与文献中观察到的相比,当前未选择的胃癌和GEJ腺癌患者中,HER2阳性状态的发生率相对较低。然而,HER2阳性与不良预后有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号